Benzodiazepine | Clinical use* | Adult dose (usual)¶ | Dose in older adults (≥65 years) | Half-life (hours) | Potential for drug interactionsΔ |
Estazolam | Sleep onset or sleep maintenance insomnia | 1 to 2 mg | 0.5 mg | Intermediate (10 to 24) | CYP3A4 to minimally active metabolite. |
Flurazepam | Sleep onset or sleep maintenance insomnia | 15 to 30 mg | 15 mg | Long (40 to 114; 120 to 160 older adults) | Non-CYP glucuronidation in liver. Active metabolite. |
Temazepam | Sleep onset or sleep maintenance insomnia | 7.5 to 30 mg | 7.5 to 15 mg | Intermediate (8 to 15) | Primarily non-CYP glucuronidation in liver to inactive metabolites. CYP3A4 to active metabolite (minor pathway, clinically insignificant). |
Triazolam | Sleep onset insomnia | 0.125 to 0.25 mg | 0.125 to 0.25 mg | Short (2 to 5) | CYP3A4. No active metabolite. |
Quazepam | Sleep onset or sleep maintenance insomnia | 7.5 to 15 mg | 7.5 mg | Long (39) | CYP3A4, CYP2C9/19. Active metabolites. |